Clinical Trial Update: Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 randomized study comparing regorafenib maintenance to placebo in metastatic gastric cancer patients who did not progress after first-line chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED